5PSQ-016 Unfavourable outcomes of blood transfusions in hospitalised anaemic patients. (March 2019)

• Record Type: Journal Article
• Authors: Alcobia, A; Soares, A; Delerue, MF; Pereira, H; Mansinho, H; Félix, J; Afonso-Silva, M; Vargas Gomes, M; Amorim, M; Plácido, M; Rabiais, S; Andreozzi, V
• Is Part Of: European journal of hospital pharmacy. Volume 26(2019)Supplement 1
• Page Start: A208
• Page End: A209
• Publication Date: 2019-03
• Subjects: Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2019-eahpconf.449
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : Background: Guidelines recommend the administration of intravenous (IV) iron to patients with anaemia due to iron deficiency. Blood transfusions are the last resource, advised only in critical patients, as they quickly raise haemoglobin (Hb) levels. However, they are also associated with deleterious outcomes. Purpose: We aimed to characterise the impact of blood transfusions in length of stay (LOS) and in-patient mortality, in a population of hospitalised anaemic patients treated with IV iron. Material and methods: This was a retrospective cohort study. Patient records from a Portuguese General Hospital, with at least one inpatient administration of iron sucrose (IS) in 2014–2015 or ferric carboxymaltose (FC) in 2016 (when FC became available), were reviewed. Adult anaemic patients with at least one Hb evaluation before and after the administration of IV iron were included. Endpoints assessed comprised the association of blood transfusions with LOS and in-patient mortality, adjusted for sex, age and baseline Hb level. Statistical analysis included a generalised linear mixed-effects model and logistic regressions, using a 5% significance level. Results: Data was collected for 1178 patients, of which 878 were treated with IS and 300 with FC. Mean age was 63.9 and 71.1 for patients treated with IS and FC, respectively. The majority of patients were female: 61.4% and 51.3% for the groups treated with IS and FC, respectively. Average baseline Hb level was 8.4 g/dl for both groups. The majority of patients required blood transfusions in both groups: 58.0% in the IS and 62.9% in the FC. Receiving at least one blood transfusion increased the LOS by 21% (95% CI: 8 to 35) in the IS group and 28% in the FC group (95% CI: 3 to 60). The in-hospital mortality risk increased 2.5-fold (95% CI: 1.4 to 4.3) in patients treated with IS and who received a blood transfusion. As for patients treated with FC, in-hospital mortality was 4.3 times (95% CI: 1.6 to 12.1) higher in patients who received a blood transfusion. Conclusion: Blood transfusions impacted adversely on patients' outcomes across different groups. Therefore, blood transfusions should be carefully considered, in accordance with the most recent patient blood management guidelines. References and/or acknowledgements: Conflict of interest: Corporate-sponsored research or other substantive relationships: this study was developed with financial support from Vifor Pharma. The authors had no restrictions or limitations during the study.